Immunotherapy has transformed cancer treatment by utilizing the body's own immune system to combat tumors. The "Immunotherapy Advances" session features recent advances in utilizing immune responses to attack and destroy cancer cells. In contrast to old-fashioned therapies like chemotherapy or radiation, immunotherapy is more targeted and individualized, frequently with less in the way of side effects.
Some of the most promising immunotherapy techniques involve checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Checkpoint inhibitors take the "brakes" off immune cells and enable them to target tumors successfully. CAR T-cell therapy manipulates a patient's own immune cells to target and kill cancer with remarkable efficacy in blood malignancies. Monoclonal antibodies selectively target cancer cells while reducing damage to normal tissues.
This session also discusses the potential for biomarkers to predict response in patients and to personalize treatment strategies. Combination therapies are being increasingly researched by scientists, combining immunotherapy with chemotherapy, radiation, or drugs that target cancerous cells to optimize results. New strategies such as neoantigen vaccines and oncolytic viruses are broadening the scope of immunotherapy to many types of cancers.
They will receive insights into state-of-the-art immunotherapy approaches, clinical uses, and emerging innovations that are defining the future of cancer therapy."
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
